Serina Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Serina Therapeutics, Inc. (SER) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$19.27 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-25
- Serina Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$19.27M.
- Serina Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$11.21M, a 312.70% decline from fiscal 2023.
- Serina Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $5.27M.
- Serina Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2021 was -$8.69M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$19.27M 10-K · filed 2026-03-25 | |
| 2024-12-31 | -$11.21M 10-K · filed 2026-03-25 | -$11.14M 10-K · filed 2025-03-24 |
| 2023-12-31 | $5.27M 10-K · filed 2025-03-24 | |
| 2021-12-31 | -$8.69M 10-K · filed 2022-03-29 | |
| 2020-12-31 | -$9.36M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |